How much funding has Stipple Bio raised?

Stipple Bio has raised $100.0M in total funding, most recently a Series A round.

Who are Stipple Bio's investors?

Stipple Bio's investors include Andreessen Horowitz, RA Capital Management.

When was Stipple Bio founded?

Stipple Bio was founded in 2022.

Where is Stipple Bio headquartered?

Stipple Bio is headquartered in Cambridge, Massachusetts, United States.

What industry is Stipple Bio in?

Stipple Bio operates in Biotech, Oncology.

Stipple Bio

Epitope-level precision for safer cancer therapies

Cambridge, United States · Founded 2022 · $100.0M raised

Biotech

Oncology

Headquarters: Cambridge, Massachusetts
Founded: 2022
Business Model: B2B
Website: stipple.bio

Total Funding: $100.0M
Last Round: $100.0M Series AApr 2026
Rounds: 1

About

Stipple Bio is a Cambridge, MA-based biotechnology company developing precision cancer therapies by targeting tumor-specific cell surface epitopes. Founded in 2022 by Dr. Aaron Ring (Fred Hutch) and Dr. Aashish Manglik (UCSF), the company raised a $100M oversubscribed Series A led by RA Capital in April 2026. Its epitope-level precision approach aims to improve therapeutic index and unlock previously intractable oncology targets.

Summary

Stipple Bio is a Biotech company based in Cambridge, United States, founded in 2022. It has raised $100.0M in total across 1 round, most recently a $100.0M Series A round in Apr 2026. Investors include Andreessen Horowitz and RA Capital Management.

LinkedIn X (Twitter)